CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 103 enrolled
Drug / intervention
PF-06412562 3mg BID +3 moredrug
Likely dose
PF-06412562 3mg BIDfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02418819
NCT02418819Phase 1Completed
CompareCT.gov

A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, SPONSOR OPEN, PHASE 1B STUDY TO EXAMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-06412562 IN PSYCHIATRICALLY STABLE SUBJECTS WITH SCHIZOPHRENIA

Pfizer·interventional·Posted Apr 16, 2015·Updated Feb 4, 2019

In Brief

A Phase 1 clinical trial evaluating PF-06412562 3mg BID, PF-06412562 9mg BID, and 2 other interventions for Schizophrenia. Completed, enrolled 103 participants across 6 sites.

Detailed Summary

This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in subjects with schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 16, 2015
Enrollment StartApr 1, 2015
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.2 years ago

Interventions

PF-06412562 3mg BIDdrug

PF-06412562

PF-06412562 9mg BIDdrug

PF-06412562

PF-06412562 45mg BIDdrug

PF-06412562

Placeboother

Placebo